TENAX THERAPEUTICS, INC. 8-K

What Happened
Tenax Therapeutics (TENX) announced a second amendment to the executive employment agreement with its Chief Medical Officer, Dr. Stuart Rich. The Board approved the amendment on December 22, 2025, the amendment is dated January 6, 2026, and the modified work schedule is effective January 1, 2026. Under the amendment, Dr. Rich will devote an average of four days per week to his CMO duties and his annual base salary will be prorated to reflect the reduced schedule.

Key Details

• Executive: Dr. Stuart Rich, Chief Medical Officer.
• Approval date: Board approval on December 22, 2025; amendment dated January 6, 2026.
• Effective date: Modified work schedule effective January 1, 2026.
• Change: Average work commitment reduced to four days per week; annual base salary to be prorated accordingly.
• Original agreement dates referenced: Executive Employment Agreement dated January 15, 2021, previously amended June 12, 2024.

Why It Matters
This filing documents an internal change to a senior executive’s time commitment and pay structure—Dr. Rich remains CMO rather than departing. For investors, the change may modestly lower payroll expense due to prorated salary, but the company did not disclose specific dollar amounts or any change to Dr. Rich’s responsibilities. The amendment is a personnel update that signals continuity in leadership while adjusting executive compensation and time allocation.